422 related articles for article (PubMed ID: 32456274)
1. Anti-aggregation Effects of Phenolic Compounds on α-synuclein.
Ono K; Tsuji M; Yamasaki TR; Pasinetti GM
Molecules; 2020 May; 25(10):. PubMed ID: 32456274
[TBL] [Abstract][Full Text] [Related]
2. Gut Microbiome-Modified Polyphenolic Compounds Inhibit α-Synuclein Seeding and Spreading in α-Synucleinopathies.
Yamasaki TR; Ono K; Ho L; Pasinetti GM
Front Neurosci; 2020; 14():398. PubMed ID: 32431588
[TBL] [Abstract][Full Text] [Related]
3. Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity.
Takahashi R; Ono K; Takamura Y; Mizuguchi M; Ikeda T; Nishijo H; Yamada M
J Neurochem; 2015 Sep; 134(5):943-55. PubMed ID: 26016728
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneity in gut microbiota drive polyphenol metabolism that influences α-synuclein misfolding and toxicity.
Ho L; Zhao D; Ono K; Ruan K; Mogno I; Tsuji M; Carry E; Brathwaite J; Sims S; Frolinger T; Westfall S; Mazzola P; Wu Q; Hao K; Lloyd TE; Simon JE; Faith J; Pasinetti GM
J Nutr Biochem; 2019 Feb; 64():170-181. PubMed ID: 30530257
[TBL] [Abstract][Full Text] [Related]
5. The Oligomer Hypothesis in α-Synucleinopathy.
Ono K
Neurochem Res; 2017 Dec; 42(12):3362-3371. PubMed ID: 28828740
[TBL] [Abstract][Full Text] [Related]
6. Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies.
Uchihara T; Giasson BI
Acta Neuropathol; 2016 Jan; 131(1):49-73. PubMed ID: 26446103
[TBL] [Abstract][Full Text] [Related]
7. [Prion-like Propagation of Pathological α-Synuclein in Vivo].
Masuda-Suzukake M; Hasegawa M
Yakugaku Zasshi; 2019; 139(7):1007-1013. PubMed ID: 31257247
[TBL] [Abstract][Full Text] [Related]
8. Familial Parkinson disease mutations influence α-synuclein assembly.
Ono K; Ikeda T; Takasaki J; Yamada M
Neurobiol Dis; 2011 Sep; 43(3):715-24. PubMed ID: 21684335
[TBL] [Abstract][Full Text] [Related]
9. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
10. Alpha-synuclein assembly as a therapeutic target of Parkinson's disease and related disorders.
Ono K; Hirohata M; Yamada M
Curr Pharm Des; 2008; 14(30):3247-66. PubMed ID: 19075704
[TBL] [Abstract][Full Text] [Related]
11. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles.
Meade RM; Fairlie DP; Mason JM
Mol Neurodegener; 2019 Jul; 14(1):29. PubMed ID: 31331359
[TBL] [Abstract][Full Text] [Related]
13. Vesicle trafficking and lipid metabolism in synucleinopathy.
Fanning S; Selkoe D; Dettmer U
Acta Neuropathol; 2021 Apr; 141(4):491-510. PubMed ID: 32607605
[TBL] [Abstract][Full Text] [Related]
14. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.
Galvin JE; Uryu K; Lee VM; Trojanowski JQ
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13450-5. PubMed ID: 10557341
[TBL] [Abstract][Full Text] [Related]
15. A glimpse into the structural properties of α-synuclein oligomers.
Santos J; Pallarès I; Ventura S
Biofactors; 2024; 50(3):439-449. PubMed ID: 38063360
[TBL] [Abstract][Full Text] [Related]
16. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
17. Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H β-synuclein.
Sekigawa A; Fujita M; Sekiyama K; Takamatsu Y; Hatano T; Rockenstein E; La Spada AR; Masliah E; Hashimoto M
Mol Brain; 2012 Sep; 5():34. PubMed ID: 23013868
[TBL] [Abstract][Full Text] [Related]
18. MUFA synthesis and stearoyl-CoA desaturase as a new pharmacological target for modulation of lipid and alpha-synuclein interaction against Parkinson's disease synucleinopathy.
Kula J; Kuter KZ
Neuropharmacology; 2024 May; 249():109865. PubMed ID: 38342377
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA.
Bétemps D; Verchère J; Brot S; Morignat E; Bousset L; Gaillard D; Lakhdar L; Melki R; Baron T
Acta Neuropathol Commun; 2014 Mar; 2():29. PubMed ID: 24624994
[TBL] [Abstract][Full Text] [Related]
20. Histones facilitate α-synuclein aggregation during neuronal apoptosis.
Jiang P; Gan M; Yen SH; McLean PJ; Dickson DW
Acta Neuropathol; 2017 Apr; 133(4):547-558. PubMed ID: 28004278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
